Open AccessHow I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective
Author(s) -
Chetasi Talati,
Diedra Frantz,
Amber Lubas,
Christopher Salamanca,
Katherine Tobon,
Timothy Kubal
Publication year - 2020
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2019-0781
Subject(s) - medicine , myeloid leukemia , perspective (graphical) , multidisciplinary team , multidisciplinary approach , intensive care medicine , oncology , nursing , social science , sociology , artificial intelligence , computer science
Historically, patients with acute myeloid leukemia received intensive chemotherapy requiring hospitalization, which can diminish quality of life and increase healthcare costs. The introduction of new therapies facilitated a shift toward outpatient therapy, which requires coordination of a multidisciplinary team, thorough patient evaluation, careful preparation and rigorous patient monitoring. Many patients are candidates for multiple treatment approaches; we generally employ CPX-351 (Vyxeos®) as an intensive outpatient approach and venetoclax (Venclyxto/Venclexta®) plus hypomethylating agents as a lower-intensity approach, with 2–3 visits/week during treatment. Treatment infusions are scheduled in the morning to leave sufficient time for transfusions and other supportive care later the same day, to prevent additional visits. With careful planning and patient monitoring, acute myeloid leukemia treatment can be successfully administered in the outpatient setting.